Suppr超能文献

原发性高血压患者对慢性酮色林治疗的血流动力学和体液反应

Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.

作者信息

Fagard R, Fiocchi R, Lijnen P, Staessen J, Moerman E, de Schaepdryver A, Amery A

出版信息

Br Heart J. 1984 Feb;51(2):149-56. doi: 10.1136/hrt.51.2.149.

Abstract

Ketanserin (120 mg/day) or placebo was given orally to 14 patients with mild to moderate essential hypertension according to a double blind crossover protocol, each treatment period lasting six weeks. Resting intra-arterial pressure in the recumbent position was reduced from 150/84 to 141/77 mm Hg; the hypotensive effect persisted throughout an uninterrupted graded exercise test to the point of exhaustion. The haemodynamic effects were similar at rest and during exercise. Overall, systemic vascular resistance decreased by 14%, heart rate fell by 5%, but stroke volume and cardiac output increased. Mean pulmonary arterial pressure and capillary wedge pressure were not significantly affected, but pulmonary vascular resistance decreased by 15%. The pressor response to methoxamine was significantly reduced by ketanserin. Both plasma noradrenaline and adrenaline concentrations increased, plasma renin activity and angiotensin II concentration decreased, and plasma aldosterone concentration was unchanged. The data indicate that ketanserin induces arteriolar dilatation, possibly related to an alpha-1-antagonistic action and to a reduced circulating angiotensin II concentration. The haemodynamic response is complex, and an increase in cardiac output limits the hypotensive effect. There is no firm evidence of an effect on venous tone as cardiac filling pressures do not change.

摘要

按照双盲交叉试验方案,对14例轻至中度原发性高血压患者口服酮色林(120毫克/天)或安慰剂,每个治疗期持续6周。卧位时的静息动脉内压从150/84毫米汞柱降至141/77毫米汞柱;在不间断的分级运动试验直至疲劳时,降压效果持续存在。静息和运动时的血流动力学效应相似。总体而言,全身血管阻力降低14%,心率下降5%,但每搏输出量和心输出量增加。平均肺动脉压和毛细血管楔压未受显著影响,但肺血管阻力降低15%。酮色林显著降低了对甲氧明的升压反应。血浆去甲肾上腺素和肾上腺素浓度均升高,血浆肾素活性和血管紧张素II浓度降低,血浆醛固酮浓度未变。数据表明,酮色林可诱导小动脉扩张,可能与α-1拮抗作用及循环中血管紧张素II浓度降低有关。血流动力学反应较为复杂,心输出量增加限制了降压效果。由于心脏充盈压未改变,尚无确凿证据表明其对静脉张力有影响。

相似文献

1
2
Hemodynamic response to chronic ketanserin treatment in essential hypertension.
J Cardiovasc Pharmacol. 1985;7 Suppl 7:S128-9. doi: 10.1097/00005344-198500077-00038.
4
Ketanserin: haemodynamic effects and mechanism of action.
J Hypertens Suppl. 1986 Apr;4(1):S7-12.
6
Mechanism of antihypertensive action of ketanserin in man.
Br Med J (Clin Res Ed). 1983 Aug 6;287(6389):381-3. doi: 10.1136/bmj.287.6389.381-a.
9
Acute haemodynamic and humoral responses to felodipine and metoprolol in mild hypertension.
Eur J Clin Pharmacol. 1987;32(1):71-5. doi: 10.1007/BF00609960.

引用本文的文献

2
Influence of antihypertensive drugs on exercise capacity.
Drugs. 1993;46 Suppl 2:32-6. doi: 10.2165/00003495-199300462-00007.
3
Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics.
Br J Clin Pharmacol. 1987 Nov;24(5):599-606. doi: 10.1111/j.1365-2125.1987.tb03218.x.
5
Effects of ketanserin on systemic and regional haemodynamics in patients with essential hypertension.
Drugs. 1988;36 Suppl 1:120-2. doi: 10.2165/00003495-198800361-00023.
6
Ketanserin concentration-effect relationships in individual hypertensive patients.
Br J Clin Pharmacol. 1988 Jul;26(1):61-4. doi: 10.1111/j.1365-2125.1988.tb03364.x.
7
Controlled trial of ketanserin in hypertension.
Br J Clin Pharmacol. 1985 Jul;20(1):37-40. doi: 10.1111/j.1365-2125.1985.tb02795.x.
10
Ketanserin in the treatment of diabetes-associated hypertension.
Drugs. 1988;36 Suppl 1:35-43. doi: 10.2165/00003495-198800361-00007.

本文引用的文献

1
Cardioaccelerator action of angiotensin.
Am J Physiol. 1962 Feb;202:237-40. doi: 10.1152/ajplegacy.1962.202.2.237.
2
Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
Br Med J (Clin Res Ed). 1982 Oct 16;285(6348):1069-71. doi: 10.1136/bmj.285.6348.1069.
3
Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.
Br Med J (Clin Res Ed). 1982 Feb 20;284(6315):537-9. doi: 10.1136/bmj.284.6315.537.
5
Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.
Life Sci. 1981 Mar 2;28(9):1015-22. doi: 10.1016/0024-3205(81)90747-5.
6
Mechanism of the hypotensive effect of ketanserin.
J Cardiovasc Pharmacol. 1982 Sep-Oct;4(5):829-38. doi: 10.1097/00005344-198209000-00020.
7
Is ketanserin a D receptor antagonist?
Lancet. 1983 Mar 26;1(8326 Pt 1):703-4.
8
Cardiovascular effects in the rat of ketanserin, a novel 5-hydroxytryptamine receptor blocking agent.
J Pharm Pharmacol. 1982 Jul;34(7):442-5. doi: 10.1111/j.2042-7158.1982.tb04753.x.
9
Ketanserin in acute superficial thrombophlebitis.
Lancet. 1982 Aug 21;2(8295):440-1. doi: 10.1016/s0140-6736(82)90469-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验